ACGN · Aceragen, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $902.0K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $12.19M | $16.38M | $24.77M | $34.85M | $41.84M | $50.65M |
| SG&A | $12.21M | $9.98M | $11.91M | $12.48M | $15.42M | $16.72M |
| Total Operating Expenses | $32.68M | $27.67M | $36.69M | $47.52M | $61.62M | $67.37M |
| D&A | $100.0K | $100.0K | $100.0K | $100.0K | $400.0K | $700.0K |
| Operating Income | ($27.82M) | ($27.67M) | ($36.69M) | ($46.07M) | ($60.96M) | ($66.47M) |
| Interest Expense | - | $7.0K | $3.0K | - | $11.0K | $50.0K |
| Income Tax | ($6.32M) | - | - | - | - | - |
| Net Income | ($23.36M) | $98.09M | ($112.66M) | ($56.52M) | ($59.88M) | ($65.98M) |
| EPS - Basic | ($7.18) | ($3.33) | - | - | - | - |
| EPS - Diluted | ($7.18) | ($3.33) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.04M | $32.55M | $33.23M | $40.02M | $71.43M | $112.63M |
| Accounts Receivable | $4.21M | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $5.20M | $565.0K | $329.0K | $457.0K | $1.13M | $1.33M |
| Current Assets | $17.86M | $34.04M | $41.35M | $46.27M | $72.81M | $116.62M |
| Total Assets | $101.11M | $34.86M | $42.40M | $47.49M | $73.02M | $118.42M |
| Current Liabilities | $21.42M | $4.86M | $7.03M | $54.52M | $9.02M | $10.11M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $62.17M | $5.41M | $133.57M | $58.66M | $9.03M | $10.72M |
| Stockholders' Equity | $11.83M | $29.45M | ($91.17M) | ($11.17M) | $63.99M | $107.69M |
| Retained Earnings | ($758.82M) | ($735.46M) | ($833.55M) | ($720.89M) | ($664.38M) | ($604.49M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($24.50M) | ($24.60M) | ($33.77M) | ($44.50M) | ($51.92M) | ($28.20M) |
| Investing Cash Flow | $5.48M | $4.50M | ($1.69M) | ($2.40M) | $215.0K | $31.37M |
| Financing Cash Flow | ($1.49M) | $19.41M | $28.67M | $15.49M | $10.19M | $50.92M |
| CapEx | - | - | $8.0K | $11.0K | $75.0K | $206.0K |
| Free Cash Flow | - | - | ($33.78M) | ($44.51M) | ($51.99M) | ($28.41M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -7368.8% |
| EBITDA margin | - | - | - | - | - | -7291.2% |
| Net margin | - | - | - | - | - | -7315.3% |
| Free cash flow margin | - | - | - | - | - | -3149.6% |
| FCF / Net income | - | - | 0.30 | 0.79 | 0.87 | 0.43 |
| R&D / Revenue | - | - | - | - | - | 5615.6% |
| SG&A / Revenue | - | - | - | - | - | 1853.2% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -23.1% | 281.4% | -265.7% | -119.0% | -82.0% | -55.7% |
| Return on equity | -197.5% | 333.0% | 123.6% | 506.0% | -93.6% | -61.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.83 | 7.00 | 5.89 | 0.85 | 8.07 | 11.54 |
| Quick ratio | 0.83 | 7.00 | 5.89 | 0.85 | 8.07 | 11.54 |
| Cash ratio | 0.56 | 6.69 | 4.73 | 0.73 | 7.92 | 11.14 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -3953.3x | -12229.0x | - | -5541.5x | -1329.3x |
| Equity multiplier | 8.55 | 1.18 | -0.47 | -4.25 | 1.14 | 1.10 |
| Liabilities / Assets | 0.61 | 0.16 | 3.15 | 1.24 | 0.12 | 0.09 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | 0.01 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | -94.4% |
| Revenue CAGR (3y) | - | - | - | - | - | 131.2% |
| Revenue CAGR (5y) | - | - | - | - | - | 77.6% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -0.5% | 24.6% | 20.4% | 24.4% | 8.3% | -71.5% |
| Net income growth (YoY) | - | - | -99.3% | 5.6% | 9.2% | -71.9% |
| EPS growth (YoY) | -115.6% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 24.1% | 14.4% | -83.0% | 0.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -59.8% | - | -716.4% | - | -40.6% | 4.2% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Aceragen against the 5 most active filers in the same SIC group.